Open AccessEffectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
Author(s) -
Al Dhafiri Mahdi,
Sicre de Fontbrune Flore,
Marinho Eduardo,
Deschamps Lydia,
DiLucca Julie,
Crickx Beatrice,
Descamps Vincent
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2137
Subject(s) - medicine , lenalidomide , chop , lymphoma , refractory (planetary science) , radiation therapy , diffuse large b cell lymphoma , oncology , dermatology , multiple myeloma , physics , astrobiology
Key Clinical Message The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.